Day One of DTC Drug Ad Meeting

Researchers Urge FDA To Require Prescription Drug Risks To Be Placed Prominently in Ads

Article highlights:

  • Information about drug risks must be presented in a more consumer-friendly format and displayed more prominently in ads (Ruth Day, Assistant Professor at Duke University)
  • After reading or viewing a drug ad, “80% of people can recall what a drug’s benefits are; 20% can recall what the side effects are.” (Ruth Day)
  • FDA should have a mandatory review of ads before they are released (AstraZeneca, written testimony)
  • FDA shouldn’t micromanage drug ads (John Kamp, Coalition for Healthcare Communication
  • It’s critical, from a public health standpoint, that the advertisements are truthful and balanced (Janet Woodcock, FDA Deputy Commissioner for Operations)

Leave a Reply

Your email address will not be published. Required fields are marked *